A Reflection On BTD And RMAT Designations
Thought Leadership In Association With Lachman Consultants
Sponsored by:
The continuing interest in cell and gene therapies is reflected by the 800+ active investigational new drug (IND) applications within the field that are on file with the US Food and Drug Administration (FDA).1 This trend is only set to increase, with the FDA foreseeing the approval of 10–20 cell and gene therapy (CGT) products per year by 2025.2
Sponsored by: